Skip to Content
Merck
All Photos(1)

Documents

Safety Information

P0100

Sigma-Aldrich

Psilocybin

≥98% (HPLC), solid

Synonym(s):

3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl phosphate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C12H17N2O4P
CAS Number:
520-52-5
Molecular Weight:
284.25
EC Number:
208-294-4
MDL number:
MFCD01310431
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

solid

drug control

USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada

solubility

H2O: >20 mg/mL

storage temp.

−20°C

SMILES string

CN(C)CCc1c[nH]c2cccc(OP(O)(O)=O)c12

Biochem/physiol Actions

Psilocybin is a hallucinogenic serotonin 1A and 2A agonist and psychotomimetic. It is the minor hallucinogenic component of Teonanácatl, the sacred mushroom of Mexico. Psilocybin produces muscle relaxation, dilation of pupils, vivid visual and auditory distortions, and emotional disturbances.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H315,H319,H370

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

P0100-BULK:
P0100-VAR:
P0100-5MG:
P0100-25MG:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jonathan P Roiser et al.
Current biology : CB, 22(7), R231-R233 (2012-04-14)
Two recent studies report changes in human brain responses after exposure to psilocybin, the active ingredient of hallucinogenic mushrooms. Psilocybin increased sensory cortex responses during emotional recollection, but decreased resting-state blood flow in prefrontal cortex, with potential implications for treating depression.
Opening doors of perception: psychedelic drugs and end-of-life care.
Norra Macready
Journal of the National Cancer Institute, 104(21), 1619-1620 (2012-10-30)
Erich Studerus et al.
PloS one, 7(2), e30800-e30800 (2012-03-01)
Responses to hallucinogenic drugs, such as psilocybin, are believed to be critically dependent on the user's personality, current mood state, drug pre-experiences, expectancies, and social and environmental variables. However, little is known about the order of importance of these variables
Hallucinogen actions on human brain revealed.
Hyeong-Min Lee et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(6), 1820-1821 (2012-02-07)
Michael Kometer et al.
Biological psychiatry, 72(11), 898-906 (2012-05-15)
Serotonin (5-HT) 1A and 2A receptors have been associated with dysfunctional emotional processing biases in mood disorders. These receptors further predominantly mediate the subjective and behavioral effects of psilocybin and might be important for its recently suggested antidepressive effects. However
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service